[go: up one dir, main page]

WO2002042426A3 - Systeme de transporteur pour apport specifique de genes au niveau de la paroi arterielle - Google Patents

Systeme de transporteur pour apport specifique de genes au niveau de la paroi arterielle Download PDF

Info

Publication number
WO2002042426A3
WO2002042426A3 PCT/US2001/047072 US0147072W WO0242426A3 WO 2002042426 A3 WO2002042426 A3 WO 2002042426A3 US 0147072 W US0147072 W US 0147072W WO 0242426 A3 WO0242426 A3 WO 0242426A3
Authority
WO
WIPO (PCT)
Prior art keywords
artery wall
carrier system
gene delivery
specific artery
wall gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/047072
Other languages
English (en)
Other versions
WO2002042426A2 (fr
Inventor
Lei Yu
Sung Wan Kim
Jae-Woon Nah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Priority to AU2002241603A priority Critical patent/AU2002241603A1/en
Priority to US10/416,381 priority patent/US7264969B1/en
Publication of WO2002042426A2 publication Critical patent/WO2002042426A2/fr
Publication of WO2002042426A3 publication Critical patent/WO2002042426A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Selon cette invention, un peptide de liaison de la paroi artérielle (AWBP) basé sur le domaine de liaison avec une cellule de la paroi artérielle d'une alipoprotéine B-100 a été conjugué avec un squelette cationique conçu de manière à former un complexe avec un acide nucléique, pour produire une composition qui améliore le transfert de gènes vers les cellules de paroi artérielle. Le squelette cationique peut être par exemple de la poly(L-lysine) comportant un greffage de poly(éthylène glycol) (PEG-g-PLL). L'invention concerne également des procédés de fabrication et d'utilisation de cette composition pour le transfert de gènes.
PCT/US2001/047072 2000-11-10 2001-11-09 Systeme de transporteur pour apport specifique de genes au niveau de la paroi arterielle Ceased WO2002042426A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002241603A AU2002241603A1 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery
US10/416,381 US7264969B1 (en) 2000-11-10 2001-11-09 Carrier system for specific artery wall gene delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24732000P 2000-11-10 2000-11-10
US60/247,320 2000-11-10

Publications (2)

Publication Number Publication Date
WO2002042426A2 WO2002042426A2 (fr) 2002-05-30
WO2002042426A3 true WO2002042426A3 (fr) 2002-10-17

Family

ID=22934463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047072 Ceased WO2002042426A2 (fr) 2000-11-10 2001-11-09 Systeme de transporteur pour apport specifique de genes au niveau de la paroi arterielle

Country Status (2)

Country Link
AU (1) AU2002241603A1 (fr)
WO (1) WO2002042426A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420068B (zh) * 2019-11-13 2021-11-09 浙江大学 聚乙二醇-树枝状聚赖氨酸/酸酐-顺铂复合物及其制备方法和应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
FR2835829B1 (fr) * 2002-02-13 2007-09-14 Centre Nat Rech Scient Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications
EP1732383A4 (fr) 2004-04-06 2007-05-02 Cedars Sinai Medical Center Prevention et traitement des maladies vasculaires avec des vecteurs de virus associes aux adenovirus de recombinaison codant l'apolipoproteine a-i et l'apolipoproteine a-i milano
US20100028402A1 (en) * 2006-10-25 2010-02-04 Marina Dobrovolskaia Nanoparticle-based anticoagulant
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
US9205141B2 (en) 2010-11-12 2015-12-08 Cardio Vax, Llc Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN112226207B (zh) * 2020-10-28 2021-10-22 兰州大学 一种高稳定性固-固复合相变材料及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAH ET AL.: "Artery wall binding peptide-poly (ethylene glycol)-grafted-poly (L-Lysine)-based gene delivery to artery wall cells", JOURNAL OF CONTROLLED RELEASE, vol. 78, no. 1-3, January 2002 (2002-01-01), pages 273 - 284, XP002953705 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111420068B (zh) * 2019-11-13 2021-11-09 浙江大学 聚乙二醇-树枝状聚赖氨酸/酸酐-顺铂复合物及其制备方法和应用

Also Published As

Publication number Publication date
WO2002042426A2 (fr) 2002-05-30
AU2002241603A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
WO2002042426A3 (fr) Systeme de transporteur pour apport specifique de genes au niveau de la paroi arterielle
EP1541690A3 (fr) Transfer de mARN à l'aide de composés polycationiques
WO1995031541A3 (fr) Methodes et compositions a base de ribozymes pour le traitement de la restenose et du cancer
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
WO2001075087A8 (fr) Variantes de lasubtilisine
AU3999495A (en) Peptide nucleic acid conjugates
WO1996014408A3 (fr) Sequence nucleotidique codant l'enzyme i-scei et ses utilisations
WO2004097017A3 (fr) Compositions pour ameliorer le transport de molecules dans des cellules
EP1808180A3 (fr) GP 100 modifié et ses utilisations
AU6097100A (en) Crosslinked dna condensate compositions and gene delivery methods
WO2000052155A3 (fr) Recombinaison d'acides nucleiques d'insertion modifies
AU6384196A (en) Recombinational cloning using engineered recombination sites
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
EP0999279A4 (fr) Procede de transfert de genes a l'aide d'un milieu exempt de serum
WO2002024232A3 (fr) Nouvelles formulations ameliorees de vecteurs de polyethyleneimine/adn aux fins d'un apport genique in vitro
WO1997010851A3 (fr) Vehicule de transfert d'acide nucleique
MXPA03002572A (es) Secuencias de nucleotidos que intervienen en la fertilidad de los machos y metodo de su uso.
AU3178499A (en) Transfer method for specific cellular localisation of nucleic acids
TR199801933A2 (xx) Biyolojik olarak tolare edilebilen d���k molek�ler polietileniminler.
WO2000012732A3 (fr) Sequences de ciblage d'organelle
WO2000042208A8 (fr) Vecteurs d'adenovirus, lignees cellulaires d'encapsidation, compositions et procedes de preparation et d'utilisation correspondants
WO1997027276A3 (fr) Acides nucleiques codant des polypeptides presentant l'activite de la lipase d'absidia
EP1020529A3 (fr) Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales
WO2002094983A3 (fr) Complexes d'anticorps d'adn pour renforcer le transfert genique
WO2002077184A3 (fr) Conjugues d'oligonucleotide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP